In This Article:
Insiders who purchased Amplia Therapeutics Limited (ASX:ATX) shares in the past 12 months are unlikely to be deeply impacted by the stock's 10.0% decline over the past week. After taking the recent loss into consideration, the AU$524.9k worth of stock they bought is now worth AU$1.29m, indicating that their investment yielded a positive return.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Amplia Therapeutics
The Last 12 Months Of Insider Transactions At Amplia Therapeutics
In the last twelve months, the biggest single purchase by an insider was when insider Allan Moss bought AU$296k worth of shares at a price of AU$0.055 per share. Even though the purchase was made at a significantly lower price than the recent price (AU$0.14), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
In the last twelve months Amplia Therapeutics insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insider Ownership
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Insiders own 21% of Amplia Therapeutics shares, worth about AU$7.8m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About Amplia Therapeutics Insiders?
It doesn't really mean much that no insider has traded Amplia Therapeutics shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in Amplia Therapeutics and we see no evidence to suggest they are worried about the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. When we did our research, we found 5 warning signs for Amplia Therapeutics (2 are significant!) that we believe deserve your full attention.